ONM-421
/ OncoNano Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
ONM-421, a pH-responsive polymer-drug conjugate nanoparticle, delivers MMAE to solid tumors and shows antigen-independent antitumor efficacy in mice
(AACR 2026)
- "Efficacy and tolerability of ONM-421 was studied in vivo in multiple human xenograft models, HT-29, HCT-116, and FaDu compared to docetaxel (DTX) and a tissue factor targeting MMAE-ADC tisotumab vedotin (TV). ONM-421 showed stable uniformly distributed size (Dh<50nm), <1% free MMAE, and consistent pH-responsiveness over a 6-month ongoing storage stability study. ONM-421 demonstrated potent antigen-independent antitumor efficacy in multiple xenograft tumors with good tolerability in mice. The data justifies further development of ONM-421 towards IND-enabling studies."
Preclinical • Oncology • Solid Tumor • CTSB
1 to 1
Of
1
Go to page
1